TURKU, FinlandJune 27, 2022 /PRNewswire/ — Genomill, a precision diagnostics company focused on maximizing next generation sequencing (NGS) in liquid biopsies, today announces that Mike Doherty, formerly Head of Product Development at Foundation Medicine, has been appointed to the company’s Board of Directors. In addition to board membership, Mike Doherty will also serve as a strategic advisor as Genomill prepares to commercialize its breakthrough technology, Geno1®.

“We are both delighted and honored to welcome Mike to our board,” said Kalle KoskinenDirector. Mike Doherty is a well-rounded and highly experienced professional within the liquid biopsy space – having held leadership positions at Genentech, Roche, and Foundation Medicine, among others. “I am confident that adding Mike to our commercialization journey will pave the way for future success,” CEO Kalle Koskinen continued.

Genomill-patented Geno1® is a new pre-sequencing platform that enables fundamental improvements in the cost, performance and scalability of NGS. “We have already achieved a detection rate of 0.01% in dozens of molecules at this point, and this is just the tip of an iceberg,” said the company’s CTO, Manu Tamminen† “Geno1® unlocks the future of distributed kits and unlocks the full potential of NGS,” said CEO Koskinen.

Genomill is focused on introducing accurate, reliable technology that can be easily and cost-effectively integrated into the clinical diagnostic environment. “To truly revolutionize diagnostics and detection, technology must be easy to assimilate – that’s how Genomill will deliver transformative value,” added CTO Tamminen.

Geno1® is based on the unique, proprietary Bridge Capture target enrichment workflow that can be adapted to any next-generation sequencing platform, including Illumina and Ion Torrent. It can also be adapted for Nanopore sequencing with a simple modification. This technology has the potential to provide accessible, unprecedented and transformative precision diagnostic capabilities with applications in oncology, prenatal care, infectious diseases and control of antimicrobial resistance.

Genomill will present the first analytical validation data for Geno1® at the Precision Medicine World Conference, taking place in Santa Clara, California. from June 28 to 30

Presentation date: June 30, 2022

Time: 9:15 AM Pacific Time

Place: Saint Clara Congress Center, Track 6

“We are excited to share an update on our work for Geno1®, which we believe will enable improvements in performance, scalability and cost for liquid biopsies and more,” said Chief Technology Officer and Co-Founder of Genomill Manu Tamminen

Genomill’s vision is to lead the transformation of precision diagnostics with the immediate goal of bringing the full potential of liquid biopsies to more people, everywhere.

About the Precision Medicine World Conference 2022

PMWC, the “Precision Medicine World Conference”, is the largest and original annual conference dedicated to precision medicine. PMWC’s mission is to bring together recognized leaders, global top researchers and medical professionals, and innovators in the healthcare and biotechnology sectors to present practical content that helps close the knowledge gap between different sectors, catalyzing cross-functional fertilization and collaboration for the development and dissemination of precision medicine.

Since 2009, the PMWC has been recognized as an essential cornerstone for all parts of the healthcare and biotechnology community and provides an exceptional forum for the exchange of information on the latest technological developments (e.g. DNA sequencing technology), in clinical implementation ( e.g. cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors.

About Genomill

Genomill is a pioneering company in precision diagnostics. The company’s mission is to democratize the use of liquid biopsies for NGS and beyond. The company works with top commercial players and foresees a global impact on healthcare and diagnostics through its unique technological innovation.

Our proprietary and proprietary Geno1® technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and data interpretation. It truly provides resources for vertical advancement and enables fundamental improvements in cost, accuracy, scalability and turnaround time.

Kalle Koskinen
Co-founder and CEO,
Genomill Oy
Phone: +358 (0)400 107 400
email: [email protected]


View original content:

SOURCE Genomill Oy

Leave a Comment